Neuro-Oncology,
Год журнала:
2018,
Номер
20(9), С. 1155 - 1161
Опубликована: Май 6, 2018
Monitoring
patient
response
to
treatment
is
challenging
for
most
cancers,
but
it
particularly
difficult
in
glioblastoma
multiform,
the
common
and
aggressive
form
of
malignant
brain
tumor.
These
tumors
exhibit
a
high
degree
heterogeneity
which
may
not
be
reflected
biopsy.
To
determine
if
current
standard
care
effective,
glioma
patients
are
monitored
using
MRI
or
CT
scans,
an
effective
sometimes
misleading
approach
due
phenomenon
pseudoprogression.
As
such,
there
incredible
need
minimally
invasive
"liquid
biopsy"
assist
molecularly
characterizing
while
also
aiding
identification
true
progression
glioblastoma.
This
review
details
status
potential
impact
circulating
tumor
cells,
extracellular
vesicles,
ctDNA,
ctRNA,
putative
biomarkers
found
blood
patients.
mutation-based
therapy
becomes
more
prevalent
gliomas,
blood-based
analyses
offer
non-invasive
method
identifying
mutations.
The
ability
obtain
serial
biopsies"
will
provide
unique
opportunities
study
evolution
mechanisms
resistance
monitor
mutational
changes
therapy.
New England Journal of Medicine,
Год журнала:
2018,
Номер
379(10), С. 958 - 966
Опубликована: Сен. 5, 2018
Interview
with
Dr.
Tushar
Patel
on
the
role
of
extracellular
vesicles
in
physiologic
function
and
as
potential
biomarkers
for
disease.
(08:09)Download
Circulating
vesicles,
which
are
produced
by
normal
diseased
tissues
released
into
body
fluids,
can
be
markers
disease
processes
perhaps
even
tools
to
deliver
new
therapies.
Nucleic Acids Research,
Год журнала:
2019,
Номер
47(7), С. 3353 - 3364
Опубликована: Фев. 7, 2019
While
the
number
of
human
miRNA
candidates
continuously
increases,
only
a
few
them
are
completely
characterized
and
experimentally
validated.
Toward
determining
total
true
miRNAs,
we
employed
combined
in
silico
high-
experimental
low-throughput
validation
strategy.
We
collected
28
866
small
RNA
sequencing
data
sets
containing
363.7
billion
reads
excluded
falsely
annotated
low
quality
data.
Our
high-throughput
analysis
identified
65%
24
127
mature
as
likely
false-positives.
Using
northern
blotting,
validated
miRBase
entries
novel
candidates.
By
exogenous
overexpression
108
precursors
that
encode
205
confirmed
68.5%
with
confirmation
rate
going
up
to
94.4%
for
high-confidence
18.3%
Analyzing
endogenous
verified
expression
8
miRNAs
12
different
cell
lines.
In
total,
extrapolated
2300
1115
which
currently
V22.
The
will
contribute
revising
targetomes
hypothesized
by
utilizing
miRNAs.
International Journal of Molecular Sciences,
Год журнала:
2021,
Номер
22(19), С. 10373 - 10373
Опубликована: Сен. 26, 2021
Gliomas
are
the
most
common
central
nervous
system
tumors.
New
technologies,
including
genetic
research
and
advanced
statistical
methods,
revolutionize
therapeutic
approach
to
patient
reveal
new
points
of
treatment
options.
Moreover,
2021
World
Health
Organization
Classification
Tumors
Central
Nervous
System
has
fundamentally
changed
classification
gliomas
incorporated
many
molecular
biomarkers.
Given
rapid
progress
in
neuro-oncology,
here
we
compile
latest
on
prognostic
predictive
biomarkers
gliomas.
In
adult
patients,
IDH
mutations
positive
markers
have
greatest
significance.
However,
CDKN2A
deletion,
IDH-mutant
astrocytomas,
is
a
marker
highest
malignancy
grade.
presence
TERT
promoter
mutations,
EGFR
alterations,
or
combination
chromosome
7
gain
10
loss
upgrade
IDH-wildtype
astrocytoma
glioblastoma.
pediatric
H3F3A
alterations
important
which
predict
worse
outcome.
MGMT
methylation
clinical
significance
predicting
responses
temozolomide
(TMZ).
Conversely,
mismatch
repair
defects
cause
hypermutation
phenotype
poor
response
TMZ.
Finally,
discussed
liquid
biopsies,
promising
diagnostic,
prognostic,
techniques,
but
further
work
needed
implement
these
novel
technologies
practice.
Neuro-Oncology,
Год журнала:
2022,
Номер
24(6), С. 855 - 871
Опубликована: Янв. 5, 2022
There
is
an
extensive
literature
highlighting
the
utility
of
blood-based
liquid
biopsies
in
several
extracranial
tumors
for
diagnosis
and
monitoring.The
RANO
(Response
Assessment
Neuro-Oncology)
group
developed
a
multidisciplinary
international
Task
Force
to
review
English
on
biopsy
gliomas
focusing
most
frequently
used
techniques,
that
circulating
tumor
DNA,
cells,
extracellular
vesicles
blood
CSF.ctDNA
has
higher
sensitivity
capacity
represent
spatial
temporal
heterogeneity
comparison
cells.
Exosomes
have
advantages
cross
intact
blood-brain
barrier
carry
also
RNA,
miRNA,
proteins.
Several
clinical
applications
are
suggested:
establish
when
tissue
not
available,
monitor
residual
disease
after
surgery,
distinguish
progression
from
pseudoprogression,
predict
outcome.There
need
standardization
biofluid
collection,
choice
analyte,
detection
strategies
along
with
rigorous
testing
future
trials
validate
findings
enable
entry
into
practice.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(4), С. 3521 - 3521
Опубликована: Фев. 9, 2023
Glioblastoma
multiforme
(GBM)
is
the
most
common,
malignant,
poorly
promising
primary
brain
tumor.
GBM
characterized
by
an
infiltrating
growth
nature,
abundant
vascularization,
and
a
rapid
aggressive
clinical
course.
For
many
years,
standard
treatment
of
gliomas
has
invariably
been
surgical
supported
radio-
chemotherapy.
Due
to
location
significant
resistance
conventional
therapies,
prognosis
glioblastoma
patients
very
poor
cure
rate
low.
The
search
for
new
therapy
targets
effective
therapeutic
tools
cancer
current
challenge
medicine
science.
microRNAs
(miRNAs)
play
key
role
in
cellular
processes,
such
as
growth,
differentiation,
cell
division,
apoptosis,
signaling.
Their
discovery
was
breakthrough
diagnosis
diseases.
Understanding
structure
miRNAs
may
contribute
understanding
mechanisms
regulation
dependent
on
miRNA
pathogenesis
diseases
underlying
these
short
non-coding
RNAs,
including
glial
tumors.
This
paper
provides
detailed
review
latest
reports
relationship
between
changes
expression
individual
formation
development
gliomas.
use
this
also
discussed.
Signal Transduction and Targeted Therapy,
Год журнала:
2024,
Номер
9(1)
Опубликована: Дек. 1, 2024
Cancer
has
a
high
mortality
rate
across
the
globe,
and
tissue
biopsy
remains
gold
standard
for
tumor
diagnosis
due
to
its
level
of
laboratory
standardization,
good
consistency
results,
relatively
stable
samples,
accuracy
results.
However,
there
are
still
many
limitations
drawbacks
in
application
tumor.
The
emergence
liquid
provides
new
ideas
early
prognosis
Compared
with
biopsy,
advantages
treatment
various
types
cancer,
including
non-invasive,
quickly
so
on.
Currently,
detection
received
widely
attention.
It
is
now
undergoing
rapid
progress,
it
holds
significant
potential
future
applications.
Around
now,
biopsies
encompass
several
components
such
as
circulating
cells,
DNA,
exosomes,
microRNA,
RNA,
platelets,
endothelial
cells.
In
addition,
advances
identification
indicators
have
significantly
enhanced
possibility
utilizing
clinical
settings.
this
review,
we
will
discuss
application,
challenges
some
common
tumors
from
perspective
diverse
systems
tumors,
look
forward
development
prospects
field
cancer
treatment.
